Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas

Trial Profile

A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2019

At a glance

  • Drugs Deep IL-12 primed T cells (Primary)
  • Indications Lymphoma; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Torque Therapeutics
  • Most Recent Events

    • 23 Jan 2019 Status changed from planning to recruiting.
    • 29 Nov 2018 New trial record
    • 12 Nov 2018 According to a Torque Therapeutics media release, the company plans to initiate this trial in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top